Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

<p>Multivariable Cox proportional hazards models for time to progression and time to death</p>

Enregistré dans:

Détails bibliographiques
Auteur principal:	Sofie H. Tolmeijer (15313251) (author)
Autres auteurs:	Emmy Boerrigter (15313254) (author), Takayuki Sumiyoshi (15034119) (author), Edmond M. Kwan (15313257) (author), Sarah W.S. Ng (14960841) (author), Matti Annala (15313260) (author), Gráinne Donnellan (15313263) (author), Cameron Herberts (14960820) (author), Guillemette E. Benoist (15313266) (author), Paul Hamberg (15313269) (author), Diederik M. Somford (15035198) (author), Inge M. van Oort (15035171) (author), Jack A. Schalken (15313272) (author), Niven Mehra (15011036) (author), Nielka P. van Erp (15313275) (author), Alexander W. Wyatt (14960922) (author)
Publié:	2025
Sujets:	Cancer Cancer Detection and Diagnosis Methods and Technology Biomarkers Circulating tumor cells/DNA/exosomes Genitourinary Cancers Prostate cancer Liquid Biopsy
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Supplementary Table S1 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
par: Sofie H. Tolmeijer (15313251)
Publié: (2025)

Supplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
par: Sofie H. Tolmeijer (15313251)
Publié: (2025)

Supplementary Data 2 from Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
par: Ismael Fernández-Miranda (15051932)
Publié: (2025)

Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
par: Andrew A. Davis (15030032)
Publié: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
par: Nam Q. Bui (14958210)
Publié: (2025)

TS1-9 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
par: Lavanya Sivapalan (15314248)
Publié: (2025)

Supplemental Table 1 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
par: Morten Lapin (15056728)
Publié: (2025)

Supplemental Table 2 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
par: Morten Lapin (15056728)
Publié: (2025)

Supplemental Table 3 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
par: Morten Lapin (15056728)
Publié: (2025)

Supplementary Table S3 from Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
par: Jun Wang (15051911)
Publié: (2025)

Supplementary Data 1 from Early Changes in Circulating Cell-Free <i>KRAS</i> G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
par: Cloud P. Paweletz (14960112)
Publié: (2025)

Supplementary Figure S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
par: Javier Pascual (15018176)
Publié: (2025)

Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
par: Javier Pascual (15018176)
Publié: (2025)

Supplementary Figure S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
par: Javier Pascual (15018176)
Publié: (2025)

Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
par: Javier Pascual (15018176)
Publié: (2025)

Supplementary Figure S5 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
par: Javier Pascual (15018176)
Publié: (2025)

Supplementary Table S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
par: Javier Pascual (15018176)
Publié: (2025)

Supplementary Table S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
par: Javier Pascual (15018176)
Publié: (2025)

Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
par: Katleen Janssens (15053356)
Publié: (2025)

Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
par: Stephanie Lheureux (16797697)
Publié: (2025)

Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
par: Stephanie Lheureux (16797697)
Publié: (2025)

Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
par: Stephanie Lheureux (16797697)
Publié: (2025)

Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
par: Stephanie Lheureux (16797697)
Publié: (2025)

Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
par: Stephanie Lheureux (16797697)
Publié: (2025)

Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
par: Whitney L. Hensing (16461978)
Publié: (2025)

Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
par: Ruiyun Zhang (17142498)
Publié: (2025)

Table S1 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
par: N. Ari Wijetunga (15056183)
Publié: (2025)

Table S2 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
par: N. Ari Wijetunga (15056183)
Publié: (2025)

Table S3 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
par: N. Ari Wijetunga (15056183)
Publié: (2025)

Table S4 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
par: N. Ari Wijetunga (15056183)
Publié: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
par: Kala Visvanathan (14952973)
Publié: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
par: Kala Visvanathan (14952973)
Publié: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
par: Kala Visvanathan (14952973)
Publié: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
par: Kala Visvanathan (14952973)
Publié: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
par: Kala Visvanathan (14952973)
Publié: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
par: Iris van 't Erve (15054503)
Publié: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
par: Francesca Orzan (15055579)
Publié: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
par: Francesca Orzan (15055579)
Publié: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
par: Francesca Orzan (15055579)
Publié: (2025)

Figure 1 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
par: Martin Sjöström (14845882)
Publié: (2025)

Cannot write session to /tmp/vufind_sessions/sess_pp4vud8t1rqib9a7a3tmq3t21l